Compare PSIX & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSIX | NUVB |
|---|---|---|
| Founded | 1985 | 2018 |
| Country | United States | United States |
| Employees | N/A | 291 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | PSIX | NUVB |
|---|---|---|
| Price | $66.17 | $4.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $99.95 | $11.38 |
| AVG Volume (30 Days) | 749.2K | ★ 4.5M |
| Earning Date | 05-07-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.44 | $190.15 |
| Revenue Next Year | $16.18 | $62.54 |
| P/E Ratio | $17.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.10 | $1.57 |
| 52 Week High | $121.47 | $9.75 |
| Indicator | PSIX | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 53.50 | 45.66 |
| Support Level | $63.84 | $4.07 |
| Resistance Level | $69.30 | $5.55 |
| Average True Range (ATR) | 5.14 | 0.22 |
| MACD | 1.60 | 0.06 |
| Stochastic Oscillator | 89.87 | 77.78 |
Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that run on nondiesel fuels, including natural gas, propane, and gasoline. The company's products are designed to meet emission standards imposed by environmental regulatory bodies like the Environmental Protection Agency. Its products are distributed to a wide range of industrial original equipment manufacturers that supply equipment to sectors including power generation, oil and gas, material handling, airport ground support, agricultural, turf, construction and irrigation. The company generates majority of its sales from United States.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.